Rose - you are correct in what I suggest .. whilst V may not fly off the shelves presently the generics are in their sales game for the long run - they don’t have to worry about patient expiry they will have a market for decades - the medical profession will over time prescribe as a SOC naturally - as they do with statins etc Amarin and it’s shareholders / or any big pharma buying out are in a patent expiry hurry to build up a market and thus advertising is a justifiable/ risk reward expense
People need put generic hats on here - they did win the lottery -one that if appeal is unsuccessful will payout for decades to come We need win the appeal - do so Amarin can build USA market develop Europe and ROW. And /or get bought out by a big pharma wanting to do the same and seeing the drug as a profitable BO investment Covid would have blunted Amarin sales build up anyway so the loss of time / sales build up / building up BO potential is something that would have inevitably taken a dent 4 months and we will know which way the share price will blow us I am a lawyer ... I see singer briefs having positioned the appeal in very good shape you either back him in the appeal or sell up now - a shareholders choice The key thing for Amarin is making sure cash pot remains comfortable - the big criticism I have of BoD is for not waiving the renewal of share option reward mechanism during this period ... such should be on back burner until post appeal and several months thereafter to let dust settle and see where thing go Alm
News 
Market Data 
Discover 
